Singapore, June 26 -- EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, and Porton Advanced Solutions, a global leading cell and gene therapy CDMO service provider, have announced the signing of Memorandum of Understanding (MoU), which will see the two organisations collaborating on establishing and strengthening CAR T-cell therapy development and manufacturing capabilities at EVA Pharma's facilities.

Under the MOU, the partnership will prioritise the development and large-scale manufacturing of high-quality lentiviral vectors, a critical component in CAR T-cell therapies for leukemia and other blood cancers.

Porton Advanced will leverage its expertise in ...